Kangzhe Pharmaceutical (00867.HK): Innovative drug high-selective TYK2 Inhibitor CMS-D001 receives clinical trial approval notification for atopic dermatitis indications.

Zhixin Finance APP News, Kangze Pharmaceutical (00867.HK) announced that its subsidiary Demay Pharmaceuticals Co., Ltd. ("Demay Pharmaceuticals"), an innovative pharmaceutical company focused on skin health, is currently applying for an independent listing on the Main Board of the Hong Kong Stock Exchange. Demay Pharmaceuticals, together with its affiliated companies, has received the drug clinical trial approval notice for its independently developed innovative drug, CMS-D001 tablets ("CMS-D001"), issued by the National Medical Products Administration of China ("NMPA") on July 11, 2025. NMPA has agreed to conduct clinical trials to evaluate the safety and efficacy of CMS-D001 in the treatment of atopic dermatitis (AD).